Table 1.
Summary of human cases used in the present study
| Case | Diagnosis | Gender | Age | PM delay | RIN | WB |
|---|---|---|---|---|---|---|
| 1 | MA | M | 64 | 8 h 30 | 7.7 | X |
| 2 | MA | M | 56 | 5 h | 7.1 | X |
| 3 | MA | M | 67 | 5 h | 7 | X |
| 4 | MA | M | 62 | 3 h | 7.2 | X |
| 5 | MA | M | 52 | 4 h 40 m | 7.9 | X |
| 6 | MA | M | 30 | 4 h 10 m | 8.4 | X |
| 7 | MA | M | 53 | 3 h | 7.7 | X |
| 8 | MA | F | 49 | 7 h | 8.2 | X |
| 9 | MA | F | 75 | 3 h | 6.5 | X |
| 10 | MA | F | 46 | 9 h 35 m | 7.2 | X |
| 11 | MA | F | 86 | 4 h 15 m | 8.4 | X |
| 12 | MA | F | 79 | 3 h 35 m | 8 | X |
| 13 | AD | F | 89 | 8 h 50 m | 6.5 | X |
| 14 | AD | M | 81 | 7 h 30 m | 6.1 | X |
| 15 | AD | M | 91 | 7 h | 7.3 | X |
| 16 | AD | F | 86 | 9 h | 7.3 | X |
| 17 | AD | M | 92 | 7 h 45 m | 6.5 | X |
| 18 | AD | F | 84 | 7 h 45 m | 7.1 | X |
| 19 | AD | M | 82 | 5 h | 7.1 | X |
| 20 | AD | M | 75 | 8 h 15 m | 6.5 | X |
| 21 | rpAD | M | 69 | 18 h | 7.2 | X |
| 22 | rpAD | F | 85 | 6 h | 6.4 | X |
| 23 | rpAD | F | 76 | 18 h | 6 | X |
| 24 | rpAD | F | 79 | 5 h 30 m | 6.9 | X |
| 25 | rpAD | M | 83 | 5 h 30 m | 6.4 | X |
| 26 | rpAD | M | 83 | 8 h 20 m | 6.6 | X |
| 27 | rpAD | F | 81 | 6 h | 6.8 | X |
| 28 | rpAD | M | 78 | 3 h 30 m | 7 | X |
MA: middle-aged individuals with no neurological symptoms and no brain lesions on neuropathological study. AD: Alzheimer’s disease cases with typical prolonged advanced dementia, Braak stage V-VI of neurofibrillary tangle pathology, Thal phase of β-amyloid and CERAD score C; rpAD: cases with clinical and neuropathological characteristics similar to AD but with a rapid course equal to or less than 2 years. M: male; F: female; PM delay: post-mortem delay; RIN: RNA integrity number (cases assessed with RT-qPCR); WB: cases used for western blotting.